Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3393-3398

  Keel, Rebecca A ^a   Schaeftlein, Andre ^b   Kloft, Charlotte ^b   Pope, J Samuel ^a   Knauft, R Frederic ^a   Muhlebach, Marianne ^c   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ADULT; ARTICLE; BACTERIUM ISOLATION; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ERUPTION; DRUG FORMULATION; DRUG INHIBITION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MACULOPAPULAR RASH; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STEADY STATE; THROMBOCYTOPENIA;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; CYSTIC FIBROSIS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OXAZOLIDINONES; YOUNG ADULT;

EID: 79959267991     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01797-10     Document Type: Article

References (30)

1. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
2. Beringer, P., et al. 2005. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob. Agents Chemother. 49:3676-3681.
3. Bosso, J. A., P. A. Flume, and S. L. Gray. 2004. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:281-284.
4. Brickner, S. J., M. R. Barbachyn, D. K. Hutchinson, and P. R. Manninen. 2008. Linezolid (Zyvox), the first member of a completely new class of antibacterial agents for treatment of gram-positive infections. J. Med. Chem. 51:1981-1990.
5. Buerger, C., C. Joukhadar, M. Muller, and C. Kloft. 2003. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796:155-164.
6. Bulitta, J. B., et al. 2007. Systemic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507.
7. Bulitta, J. B, et al. 2010. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 54:1275-1282.
8. Cystic Fibrosis Foundation. 1995. Patient registry annual data report 1995. Cystic Fibrosis Foundation, Bethesda, MD.
9. Dasenbrook, E. C., et al. 2010. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303:2386-2392.
10. Dasenbrook, E. C., C. A. Merlo, M. Diener-West, N. Lechtzin, and M. P. Boyle. 2008. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:814-821.
11. Farrell, D. J., R. E. Mendes, J. E. Ross, and R. N. Jones. 2009. Linezolid surveillance program results for 2008 (LEADER program for 2008). Diagn. Microbiol. Infect. Dis. 65:392-403.
12. Ferrin, M., J. B. Zuckerman, A. Meagher, and E. A. Blumberg. 2002. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr. Pulmonol. 33:221-223.
13. Gales, A. C., et al. 2006. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27:300-302.
14. Gregory, P. C. 1996. Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 23:513-523.
15. Hill, R. L., et al. 2010. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J. Antimicrob. Chemother. 65:442-445.
16. Hutabarat, R. M., et al. 1991. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. Clin. Pharmacol. Ther. 49:402-409.
17. James, W. 1976. Research on obesity. Her Majesty's Stationery Office, London, United Kingdom.
18. Lindsay, C. A., and J. A. Bosso. 1993. Optimization of antibiotic therapy in cystic fibrosis patients. Clin. Pharmacokinet. 24:496-506.
19. MacGowan, A. P. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2):ii17-ii25.
20. Meagher, A. K., A. Forrest, C. R. Rayner, M. C. Birmingham, and J. J. Schentag. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553.
21. Plock, N., C. Buerger, C. Joukhada, C. Klijucar, and C. Kloft. 2007. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab. Dispos. 35:1816-1823.
22. Rayner, C. R., A. Forrest, A. K. Meagher, M. C. Birmingham, and J. J. Schentagg. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411-1423.
23. Santos, R. P., et al. 2009. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr. Pulmonol. 44:148-154.
24. Saralaya, D., et al. 2004. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J. Antimicrob. Chemother. 53:325-328.
25. Schaeftlein, A., R. Keel, J. Kuti, and C. Kloft. 2010. Linezolid concentrations in cystic fibrosis patients: evaluation of competing pharmacokinetic models, abstr. K188:48. Meeting of the German Pharmaceutical Society, October.
26. Serisier, D. J., G. Jones, and M. Carroll. 2004. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J. Cyst. Fibros. 3:61.
27. Spicuzza, L., C. Sciuto, and M. La Rosa. 2008. Safety and efficacy of long-term treatment with linezolid in cystic fibrosis: case report. J. Chemother. 20:399-401. (Pubitemid 351998911)
28. Susanto, M., and L. Z. Benet. 2002. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by p-glycoprotein transport? Pharmacol. Res. 19:457-462.
29. Swoboda, S., et al. 2010. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur. J. Clin. Pharmacol. 66:291-298.
30. Welshman, I. R., T. A. Sisson, G. L. Jungbluth, D. J. Stalker, and N. K. Hopkins. 2001. Linezolid bioavailability and the effect of food on oral bioavailability. Biopharm. Drug Dispos. 22:91-97.